SMA Industry Collaboration

Established by Cure SMA in 2016, the SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, researchers, clinicians, and nonprofit organizations.

Together, they share information, ideas, and data to advance the development of treatments for spinal muscular atrophy (SMA). The SMA Industry Collaboration addresses a wide range of scientific, clinical, and regulatory challenges. They fund research to identify the unmet needs of the SMA community and lead initiatives that ensure community priorities are reflected in the development, review, and approval of new therapies. In addition, the collaborative conducts research and drives initiatives to identify and eliminate barriers that hinder access to clinical trials and approved treatments. The goal of the SMA Industry Collaboration is to ensure that every individual affected by SMA can benefit from the latest treatment advancements. Funding support for the ICHOM Set of Patient-Centered Outcome Measures for SMA was proved by the members of the 2024 and 2025 SMA Industry Collaboration convened by Cure SMA; members included Biogen, Novartis, Scholar Rock, Biohaven Pharmaceuticals, Genentech/Roche, Alcyone Therapeutics, argenx, NMD Pharma, and SMA Europe.

TOP